Table of Contents Author Guidelines Submit a Manuscript
Journal of Osteoporosis
Volume 2012, Article ID 675984, 5 pages
http://dx.doi.org/10.1155/2012/675984
Editorial

Osteoporosis in Men

1INSERM UMR 1033, Hôpital Edouard Herriot, University of Lyon, Pavillon F, Place d’Arsonval, 69437 Lyon, France
2Department of Endocrinology, University Hospital Ghent, B-9000 Gent, Belgium
3Department of Medicine, Endocrinology, Diabetology & Clinical Nutrition, Oregon Health & Science University, Portland, OR 97239, USA

Received 24 January 2012; Accepted 24 January 2012

Copyright © 2012 Pawel Szulc et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. A. Baron, M. Karagas, J. Barrett et al., “Basic epidemiology of fractures of the upper and lower limb among americans over 65 years of age,” Epidemiology, vol. 7, no. 6, pp. 612–618, 1996. View at Google Scholar · View at Scopus
  2. D. P. Kiel, A. Eichorn, O. Intrator, R. A. Silliman, and V. Mor, “The outcomes of patients newly admitted to nursing homes after hip fracture,” American Journal of Public Health, vol. 84, no. 8, pp. 1281–1286, 1994. View at Google Scholar · View at Scopus
  3. M. Fransen, M. Woodward, R. Norton, E. Robinson, M. Butler, and A. J. Campbell, “Excess mortality or institutionalization after hip fracture: men are at greater risk than women,” Journal of the American Geriatrics Society, vol. 50, no. 4, pp. 685–690, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. D. Bliuc, N. D. Nguyen, V. E. Milch, T. V. Nguyen, J. A. Eisman, and J. R. Center, “Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women,” Journal of the American Medical Association, vol. 301, no. 5, pp. 513–521, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Trombetti, F. Herrmann, P. Hoffmeyer, M. A. Schurch, J. P. Bonjour, and R. Rizzoli, “Survival and potential years of life lost after hip fracture in men and age-matched women,” Osteoporosis International, vol. 13, no. 9, pp. 731–737, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. W. D. Leslie, S. O'Donnell, S. Jean et al., “Trends in hip fracture rates in Canada,” Journal of the American Medical Association, vol. 302, no. 8, pp. 883–889, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. B. Abrahamsen and P. Vestergaard, “Declining incidence of hip fractures and the extent of use of anti-osteoporotic therapy in Denmark 1997–2006,” Osteoporosis International, vol. 21, no. 3, pp. 373–380, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. A. A. Fisher, E. D. O'Brien, and M. W. Davis, “Trends in hip fracture epidemiology in Australia: possible impact of bisphosphonates and hormone replacement therapy,” Bone, vol. 45, no. 2, pp. 246–253, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Maravic, P. Taupin, P. Landais, and C. Roux, “Change in hip fracture incidence over the last 6 years in France,” Osteoporosis International, vol. 22, no. 3, pp. 797–801, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Chevalley, E. Guilley, F. R. Herrmann, P. Hoffmeyer, C. H. Rapin, and R. Rizzoli, “Incidence of hip fracture over a 10-year period (1991–2000): reversal of a secular trend,” Bone, vol. 40, no. 5, pp. 1284–1289, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Icks, B. Haastert, M. Wildner, C. Becker, and G. Meyer, “Trend of hip fracture incidence in Germany 1995–2004: a population-based study,” Osteoporosis International, vol. 19, no. 8, pp. 1139–1145, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Hagino, K. Furukawa, S. Fujiwara et al., “Recent trends in the incidence and lifetime risk of hip fracture in Tottori, Japan,” Osteoporosis International, vol. 20, no. 4, pp. 543–548, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. P. Szulc, F. Munoz, F. Duboeuf, F. Marchand, and P. D. Delmas, “Bone mineral density predicts osteoporotic fractures in elderly men: the MINOS study,” Osteoporosis International, vol. 16, no. 10, pp. 1184–1192, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. S. C. Schuit, M. van der Klift, A. E. Weel et al., “Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam study,” Bone, vol. 34, no. 1, pp. 195–202, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. H. A. Fink, T. L. Blackwell, B. C. Taylor et al., “Distribution and rate of clinical fractures in older men without osteoporosis: the osteoporotic fractures in men (MrOS) study,” Journal of Bone and Mineral Research, vol. 23, supplement 1, p. S79, article 1282, 2008. View at Google Scholar
  16. Writing Group for the ISCD Position Development Conference, “Diagnosis of osteoporosis in men, premenopausal women, and children,” Journal of Clinical Densitometry, vol. 7, no. 1, pp. 17–26, 2004. View at Publisher · View at Google Scholar
  17. J. A. Kanis, E. V. McCloskey, H. Johansson, A. Oden, L. J. Melton, and N. Khaltaev, “A reference standard for the description of osteoporosis,” Bone, vol. 42, no. 3, pp. 467–475, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. P. Szulc, A. Montella, and P. D. Delmas, “High bone turnover is associated with accelerated bone loss but not with increased fracture risk in men aged 50 and over: the prospective MINOS study,” Annals of the Rheumatic Diseases, vol. 67, no. 9, pp. 1249–1255, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. D. C. Bauer, P. Garnero, S. L. Harrison et al., “Biochemical markers of bone turnover, hip bone loss, and fracture in older men: the MrOS study,” Journal of Bone and Mineral Research, vol. 24, no. 12, pp. 2032–2038, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. D. C. Bauer, S. K. Ewing, J. A. Cauley, K. E. Ensrud, S. R. Cummings, and E. S. Orwoll, “Quantitative ultrasound predicts hip and non-spine fracture in men: the MrOS study,” Osteoporosis International, vol. 18, no. 6, pp. 771–777, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. D. M. Black, M. L. Bouxsein, L. M. Marshall et al., “Proximal femoral structure and the prediction of hip fracture in men: a large prospective study using QCT,” Journal of Bone and Mineral Research, vol. 23, no. 8, pp. 1326–1333, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. Y. Taes, B. Lapauw, V. Griet et al., “Prevalent fractures are related to cortical bone geometry in young healthy men at age of peak bone mass,” Journal of Bone and Mineral Research, vol. 25, no. 6, pp. 1433–1440, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. P. Szulc, S. Boutroy, N. Vilayphiou, A. Chaitou, P. D. Delmas, and R. Chapurlat, “Cross-sectional analysis of the association between fragility fractures and bone microarchitecture in older men: the STRAMBO study,” Journal of Bone and Mineral Research, vol. 26, no. 6, pp. 1358–1367, 2011. View at Publisher · View at Google Scholar
  24. http://www.shef.ac.uk/FRAX/.
  25. N. D. Nguyen, S. A. Frost, J. R. Center, J. A. Eisman, and T. V. Nguyen, “Development of a nomogram for individualizing hip fracture risk in men and women,” Osteoporosis International, vol. 18, no. 8, pp. 1109–1117, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Blaizot, P. D. Delmas, F. Marchand, R. Chapurlat, and P. Szulc, “Risk factors for peripheral fractures vary by age in older men-the prospective MINOS study,” Osteoporosis International, vol. 22, pp. 1755–1764, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. L. A. Fraser, L. Langsetmo, C. Berger et al., “Fracture prediction and calibration of a Canadian FRAX tool: a population-based report from CaMos,” Osteoporosis International, vol. 22, no. 3, pp. 829–837, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. S. K. Sandhu, N. D. Nguyen, J. R. Center, N. A. Pocock, J. A. Eisman, and T. V. Nguyen, “Prognosis of fracture: evaluation of predictive accuracy of the FRAX algorithm and Garvan nomogram,” Osteoporosis International, vol. 21, no. 5, pp. 863–871, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. P. Szulc, F. Munoz, F. Duboeuf, F. Marchand, and P. D. Delmas, “Low width of tubular bones is associated with increased risk of fragility fracture in elderly men—the MINOS study,” Bone, vol. 38, no. 4, pp. 595–602, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. F. Rivadeneira, J. J. Houwing-Duistermaat, T. J. Beck et al., “The influence of an insulin-like growth factor I gene promoter polymorphism on hip bone geometry and the risk of nonvertebral fracture in the elderly: the Rotterdam study,” Journal of Bone and Mineral Research, vol. 19, no. 8, pp. 1280–1290, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. P. Pulkkinen, J. Partanen, P. Jalovaara, and T. Jämsä, “BMD T-score discriminates trochanteric fractures from unfractured controls, whereas geometry discriminates cervical fracture cases from unfractured controls of similar BMD,” Osteoporosis International, vol. 21, pp. 1269–1276, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. E. S. Orwoll, L. M. Marshall, C. M. Nielson et al., “Finite element analysis of the proximal femur and hip fracture risk in older men,” Journal of Bone and Mineral Research, vol. 24, no. 3, pp. 475–483, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. X. Wang, A. Sanyal, P. M. Cawthon et al., “Prediction of new clinical vertebral fractures in elderly men using finite element analysis of CT scans,” Journal of Bone and Mineral Research, vol. 27, no. 4, pp. 808–816, 2012. View at Publisher · View at Google Scholar
  34. D. C. Bauer, P. Garnero, S. Litwack Harrison et al., “Type I collagen isomerization (Alpha/Beta CTX Ratio) and risk of clinical vertebral fracture in men: a prospective study,” http://www.asbmr.org/itinerary/presentationdetail.aspx?id=d3262330-281a-4261-b9a7-9a17d3efaf63.
  35. E. S. LeBlanc, C. M. Nielson, L. M. Marshall et al., “The effects of serum testosterone, estradiol, and sex hormone binding globulin levels on fracture risk in older men,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 9, pp. 3337–3346, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Amin, Y. Zhang, D. T. Felson et al., “Estradiol, testosterone, and the risk for hip fractures in elderly men from the framingham study,” American Journal of Medicine, vol. 119, no. 5, pp. 426–433, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. D. Mellström, L. Vandenput, H. Mallmin et al., “Older men with low serum estradiol and high serum SHBG have an increased risk of fractures,” Journal of Bone and Mineral Research, vol. 23, no. 10, pp. 1552–1560, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. J. A. Cauley, N. Parimi, K. E. Ensrud et al., “Serum 25-hydroxyvitamin D and the risk of hip and nonspine fractures in older men,” Journal of Bone and Mineral Research, vol. 25, no. 3, pp. 545–553, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. H. Melhus, G. Snellman, R. Gedeborg et al., “Plasma 25-hydroxyvitamin D levels and fracture risk in a community-based cohort of elderly men in Sweden,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 6, pp. 2637–2645, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. C. Ohlsson, D. Mellström, D. Carlzon et al., “Older men with low serum IGF-1 have an increased risk of incident fractures: the MrOS Sweden study,” Journal of Bone and Mineral Research, vol. 26, no. 4, pp. 865–872, 2011. View at Publisher · View at Google Scholar
  41. J. A. Langlois, C. J. Rosen, M. Visser et al., “Association between insulin-like growth factor I and bone mineral density in older women and men: the Framingham heart study,” Journal of Clinical Endocrinology and Metabolism, vol. 83, no. 12, pp. 4257–4262, 1998. View at Google Scholar · View at Scopus
  42. P. Szulc, M. O. Joly-Pharaboz, F. Marchand, and P. D. Delmas, “Insulin-like growth factor I is a determinant of hip bone mineral density in men less than 60 years of age: MINOS study,” Calcified Tissue International, vol. 74, no. 4, pp. 322–329, 2004. View at Publisher · View at Google Scholar · View at Scopus
  43. M. A. Mirza, M. K. Karlsson, D. Mellström et al., “Serum fibroblast growth factor-23 (FGF-23) and fracture risk in elderly men,” Journal of Bone and Mineral Research, vol. 26, no. 4, pp. 857–864, 2011. View at Google Scholar
  44. S. Boonen, E. S. Orwoll, D. Wenderoth, K. J. Stoner, R. Eusebio, and P. D. Delmas, “Once-weekly risedronate in men with osteoporosis: results of a 2-Year, placebo-controlled, double-blind, multicenter study,” Journal of Bone and Mineral Research, vol. 24, no. 4, pp. 719–725, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. E. S. Orwoll, N. C. Binkley, E. M. Lewiecki, U. Gruntmanis, M. A. Fries, and G. Dasic, “Efficacy and safety of monthly ibandronate in men with low bone density,” Bone, vol. 46, no. 4, pp. 970–976, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. E. S. Orwoll, P. D. Miller, J. D. Adachi et al., “Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study,” Journal of Bone and Mineral Research, vol. 25, no. 10, pp. 2239–2250, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. G. P. Trovas, G. P. Lyritis, A. Galanos, P. Raptou, and E. Constantelou, “A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers,” Journal of Bone and Mineral Research, vol. 17, no. 3, pp. 521–527, 2002. View at Google Scholar · View at Scopus
  48. E. S. Orwoll, W. H. Scheele, S. Paul et al., “The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis,” Journal of Bone and Mineral Research, vol. 18, no. 1, pp. 9–17, 2003. View at Publisher · View at Google Scholar · View at Scopus
  49. E. Orwoll, M. Ettinger, S. Weiss et al., “Alendronate for the treatment of osteoporosis in men,” The New England Journal of Medicine, vol. 343, no. 9, pp. 604–610, 2000. View at Publisher · View at Google Scholar · View at Scopus
  50. J. D. Ringe, A. Dorst, H. Faber, and K. Ibach, “Alendronate treatment of established primary osteoporosis in men: 3-Year results of a prospective, comparative, two-arm study,” Rheumatology International, vol. 24, no. 2, pp. 110–113, 2004. View at Publisher · View at Google Scholar · View at Scopus
  51. Z. M. Zhong and J. T. Chen, “Anti-fracture efficacy of risedronic acid in men: a meta-analysis of randomized controlled trials,” Clinical Drug Investigation, vol. 29, no. 5, pp. 349–357, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. J. M. Kaufman, E. Orwoll, S. Goemaere et al., “Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy,” Osteoporosis International, vol. 16, no. 5, pp. 510–516, 2005. View at Google Scholar · View at Scopus
  53. M. R. Smith, B. Egerdie, N. H. Toriz et al., “Denosumab in men receiving androgen-deprivation therapy for prostate cancer,” The New England Journal of Medicine, vol. 361, no. 8, pp. 745–755, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. M. R. Smith, R. A. Morton, K. G. Barnette et al., “Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer,” Journal of Urology, vol. 184, no. 4, pp. 1316–1321, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. M. R. Smith, S. B. Malkowicz, M. K. Brawer, M. L. Hancock, R. A. Morton, and M. S. Steiner, “Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer,” Journal of Urology, vol. 186, no. 6, pp. 2239–2244, 2011. View at Publisher · View at Google Scholar
  56. S. Boonen, G. Su, E. Incera et al., “Antifracture efficacy and safety of once-yearly zoledronic acid 5 mg in men with osteoporosis: a prospective, randomized, controlled trial,” Osteoporosis International, vol. 22, supplement 1, 2011. View at Google Scholar
  57. P. Haentjens, O. Johnell, J. A. Kanis et al., “Evidence from data searches and life-table analyses for gender-related differences in absolute risk of hip fracture after Colles' or spine fracture: Colles' fracture as an early and sensitive marker of skeletal fragility in white men,” Journal of Bone and Mineral Research, vol. 19, no. 12, pp. 1933–1944, 2004. View at Publisher · View at Google Scholar · View at Scopus
  58. M. J. Panneman, P. Lips, S. S. Sen, and R. M. C. Herings, “Undertreatment with anti-osteoporotic drugs after hospitalization for fracture,” Osteoporosis International, vol. 15, no. 2, pp. 120–124, 2004. View at Publisher · View at Google Scholar · View at Scopus
  59. A. C. Feldstein, G. Nichols, E. Orwoll et al., “The near absence of osteoporosis treatment in older men with fractures,” Osteoporosis International, vol. 16, no. 8, pp. 953–962, 2005. View at Publisher · View at Google Scholar · View at Scopus
  60. G. M. Kiebzak, G. A. Beinart, K. Perser, C. G. Ambrose, S. J. Siff, and M. H. Heggeness, “Undertreatment of osteoporosis in men with hip fracture,” Archives of Internal Medicine, vol. 162, no. 19, pp. 2217–2222, 2002. View at Publisher · View at Google Scholar · View at Scopus
  61. M. M. Chitre and W. Hayes, “3-year results of a member and physician intervention to reduce risk associated with glucocorticoid-induced osteoporosis in a health plan,” Journal of Managed Care Pharmacy, vol. 14, no. 3, pp. 281–290, 2008. View at Google Scholar · View at Scopus
  62. J. E. Brown, J. M. Sherriff, and N. D. James, “Osteoporosis in patients with prostate cancer on long-term androgen deprivation therapy: an increasing, but under-recognized problem,” BJU International, vol. 105, no. 8, pp. 1042–1043, 2010. View at Publisher · View at Google Scholar · View at Scopus